Drug Profile
Research programme: cystic fibrosis therapeutics - FoldRx
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator FoldRx Pharmaceuticals
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cystic fibrosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA
- 19 Nov 2012 Cystic Fibrosis Foundation Therapeutics and Pfizer expand their research collaboration
- 06 Oct 2010 FoldRx has been acquired by Pfizer